Enrollment complete in STENTYS Self-Apposing Stent clinical study for treatment of AMI

STENTYS S.A. (STNT.PA), a medical technology company that is commercializing the world's first and only self-apposing stent to treat Acute Myocardial Infarction (AMI), announced today that it has enrolled the 500-patient target of the international APPOSITION III study for its Self-Apposing Stent.

"The study completion is a critical milestone that was delivered on time and demonstrates the growing adoption of the Self-Apposing technology as the solution for treating heart attack patients," said Gonzague Issenmann, CEO and co-founder of STENTYS. "Given the outstanding clinical results to date and the fast pace of enrollment, we have decided to continue enrollment in order to keep accumulating clinical data."

"Cardiologists in our cath lab continue to be excited to participate in the APPOSITION III study and to have the advantage of using the STENTYS Self-Apposing Stent to treat our AMI patients," added study investigator Dr. Karel Koch, M.D., Amsterdam Medical Center, Amsterdam, the Netherlands.